# Phase 1 Open-label Study of AMX-883 Alone in Participants With AML and High-risk MDS and in Combination in Participants With AML

> **NCT07723703** · PHASE1 · RECRUITING · sponsor: **Amphista Therapeutics Ltd** · enrollment: 54 (estimated)

## Conditions studied

- Acute Myeloid Leukaemia
- High Risk Myelodysplastic Syndrome

## Interventions

- **DRUG:** AMX-883
- **DRUG:** Posaconazole

## Key facts

- **NCT ID:** NCT07723703
- **Lead sponsor:** Amphista Therapeutics Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-10-16
- **Primary completion:** 2028-12-04
- **Final completion:** 2029-04-30
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2026-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07723703

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07723703, "Phase 1 Open-label Study of AMX-883 Alone in Participants With AML and High-risk MDS and in Combination in Participants With AML". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07723703. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*